Enbrel (etanercept) is manufactured by Amgen and Wyeth and was released for market use in 1998. The drug has been approved to treat an array of conditions including severe rheumatoid arthritis, moderate to severe polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis and plaque psoriasis. In addition to the potential for causing possibly fatal infections, the http://enbrel.legalview.com [Enbrel side effects __title__ Enbrel Lawsuit] can range from a dry cough to fever, shortness of breath, swollen glands, muscle aches and chest pain, vomiting/nausea or seizures.
Of the TNF inhibitors, Cimzia is the most recent to be approved for use, approved in 2008. Cimzia (certolizumab pegol) is from makers UCB and was approved for treating Crohn's disease, which affects more than half a million Americans currently. Individuals who have taken Cimzia and are at potential risk for developing fatal infection or cancer, should contact a medical professional immediately and will likely need to discontinue use of the drug. Patients may also need further information on developing a potential http://cimzia.legalview.com [Cimzia class action __title__ Cimzia Lawyer] lawsuit in case monetary compensation is needed to pay for the medical bills associated with the http://cimzia.legalview.com [Cimzia side effects __title__ Cimzia Dangers]. If this occurs, contacting an experienced http://cimzia.legalview.com [Cimzia attorney __title__ Cimzia Law Firm] who can provide a free legal consultation may be necessary.
In addition to providing legal information about the severe medical risks associated with the TNF blockers, LegalView also recently updated two of its information portals to provide victims of both mesothelioma canc
'/>"/>
| Source: PRWeb Copyright©2008 Vocus, Inc. All rights reserved |